NOT-HL-19-683: Frequently Asked Questions (FAQ) for PA-19-166 "Implementation of shared decision making for HLBS diseases and conditions (R01 Clinical Trial Optional)"

Frequently Asked Questions (FAQ) for PA-19-166 "Implementation of shared decision making for HLBS diseases and conditions (R01 Clinical Trial Optional)"

Notice Number: NOT-HL-19-683

Key Dates
Release Date : February 13, 2019

Related Announcements
PA-19-166; Implementation of shared decision making for HLBS diseases and conditions (R01 Clinical Trial Optional)
NOT-HL-19-699

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

On January 22, 2019, NHLBI issued the Funding Opportunity Announcement (FOA) PA-19-166 Implementation of shared decision making for HLBS diseases and conditions (R01 Clinical Trial Optional).To assist potential applicants to the above-referenced FOA, this Notice provides information regarding the availability of a Frequently Asked Questions (FAQ) document.

Frequently Asked Questions (FAQ)
A Frequently Asked Questions (FAQ) document to address common questions from potential applicants regarding PA-19-166 is available at: https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/all-funding-opportunity-announcements-2867. All applicants are encouraged to review the FAQ document prior to submitting their application. We anticipate updating the FAQ document as needed and recommend that applicants check back for updates to the FAQs regularly until their submission date.

Inquiries

Please direct all inquiries to:

Susan T. Shero, BSN, MS
NHLBI/Center for Translation Research and Implementation Science (CTRIS)
Telephone: 301-827-8168
Email: sheros@nih.gov